↓ Skip to main content

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

Overview of attention for article published in Journal of Clinical Oncology, February 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news
1 news outlet
twitter
6 X users
patent
9 patents
facebook
1 Facebook page

Citations

dimensions_citation
432 Dimensions

Readers on

mendeley
403 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies
Published in
Journal of Clinical Oncology, February 2013
DOI 10.1200/jco.2012.45.3753
Pubmed ID
Authors

Tianhong Li, Hsing-Jien Kung, Philip C. Mack, David R. Gandara

Abstract

Substantial advances have been made in understanding critical molecular and cellular mechanisms driving tumor initiation, maintenance, and progression in non-small-cell lung cancer (NSCLC). Over the last decade, these findings have led to the discovery of a variety of novel drug targets and the development of new treatment strategies. Already, the standard of care for patients with advanced-stage NSCLC is shifting from selecting therapy empirically based on a patient's clinicopathologic features to using biomarker-driven treatment algorithms based on the molecular profile of a patient's tumor. This approach is currently best exemplified by treating patients with NSCLC with first-line tyrosine kinase inhibitors when their cancers harbor gain-of-function hotspot mutations in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) gene rearrangements. These genotype-based targeted therapies represent the first step toward personalizing NSCLC therapy. Recent technology advances in multiplex genotyping and high-throughput genomic profiling by next-generation sequencing technologies now offer the possibility of rapidly and comprehensively interrogating the cancer genome of individual patients from small tumor biopsies. This advance provides the basis for categorizing molecular-defined subsets of patients with NSCLC in whom a growing list of novel molecularly targeted therapeutics are clinically evaluable and additional novel drug targets can be discovered. Increasingly, practicing oncologists are facing the challenge of determining how to select, interpret, and apply these new genetic and genomic assays. This review summarizes the evolution, early success, current status, challenges, and opportunities for clinical application of genotyping and genomic tests in therapeutic decision making for NSCLC.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 403 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
United States 2 <1%
Austria 1 <1%
Brazil 1 <1%
Czechia 1 <1%
Netherlands 1 <1%
Mexico 1 <1%
India 1 <1%
Unknown 393 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 78 19%
Student > Ph. D. Student 65 16%
Student > Bachelor 44 11%
Other 40 10%
Student > Master 36 9%
Other 69 17%
Unknown 71 18%
Readers by discipline Count As %
Medicine and Dentistry 144 36%
Agricultural and Biological Sciences 67 17%
Biochemistry, Genetics and Molecular Biology 67 17%
Pharmacology, Toxicology and Pharmaceutical Science 9 2%
Computer Science 7 2%
Other 29 7%
Unknown 80 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 February 2022.
All research outputs
#2,191,138
of 25,374,917 outputs
Outputs from Journal of Clinical Oncology
#5,206
of 22,047 outputs
Outputs of similar age
#21,692
of 296,802 outputs
Outputs of similar age from Journal of Clinical Oncology
#39
of 209 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,047 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,802 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 209 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.